ハシモト　ヤスノブ   HASHIMOTO Yasunobu   橋本　恭伸    所属   医学部 医学科（東京女子医科大学病院）    職種   講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
掲載誌名	正式名：International journal of urology : official journal of the Japanese Urological Association 略　 称：Int J Urol ISSNコード：14422042/09198172
掲載区分	国外
巻・号・頁	16(3),pp.287-292
著者・共著者	Iida Shoichi, Kondo Tsunenori, Kobayashi Hirohito, Hashimoto Yasunobu, Goya Nobuyuki, Tanabe Kazunari
発行年月	2009/03
概要	OBJECTIVES:To report on the long-term clinical outcome of high-grade (G3) non-muscle-invasive bladder cancer (NMIBC) patients treated at a single institution.METHODS:A retrospective analysis of 93 patients with NMIBC treated between January 1991 and September 2005 was performed. Patients were divided into three groups on the basis of treatment they received after transurethral resection (TUR) of the bladder. Forty-seven patients received adjuvant intravesical epirubicine after TUR of the bladder (Group 1). Twenty-four patients received intravesical bacillus Calmette-Guérin (BCG) (Group 2). A radical cystectomy (RC) was performed on twenty-two patients (Group 3).RESULTS:Median follow up was 68.7 months. Overall, thirty patients (33%) experienced tumor recurrence. The survival rates of Group 3 were significantly higher than the 71 patients undergoing conservative therapy (Group 1 and 2). There was no statistically significant difference between Group 1 and 2, but treatment failure in patients treated with epirubicine was significantly higher than in those with BCG. Cases without concomitant carcinoma in situ (CIS) showed statistically significantly higher survival rates than those with concomitant CIS.CONCLUSIONS:RC provides excellent survival rates in patients with high-grade NMIBC. Adjuvant therapy with BCG after a complete TUR of the bladder may be an effective treatment for high-grade NMIBC. If a conservative treatment is preferred to RC, co-existence of a concomitant CIS should be considered with caution.
DOI	10.1111/j.1442-2042.2008.02239.x
PMID	19207115